Cargando…

Towards a “Sample-In, Answer-Out” Point-of-Care Platform for Nucleic Acid Extraction and Amplification: Using an HPV E6/E7 mRNA Model System

The paper presents the development of a “proof-of-principle” hands-free and self-contained diagnostic platform for detection of human papillomavirus (HPV) E6/E7 mRNA in clinical specimens. The automated platform performs chip-based sample preconcentration, nucleic acid extraction, amplification, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulliksen, Anja, Keegan, Helen, Martin, Cara, O'Leary, John, Solli, Lars A., Falang, Inger Marie, Grønn, Petter, Karlgård, Aina, Mielnik, Michal M., Johansen, Ib-Rune, Tofteberg, Terje R., Baier, Tobias, Gransee, Rainer, Drese, Klaus, Hansen-Hagge, Thomas, Riegger, Lutz, Koltay, Peter, Zengerle, Roland, Karlsen, Frank, Ausen, Dag, Furuberg, Liv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253481/
https://www.ncbi.nlm.nih.gov/pubmed/22235204
http://dx.doi.org/10.1155/2012/905024
Descripción
Sumario:The paper presents the development of a “proof-of-principle” hands-free and self-contained diagnostic platform for detection of human papillomavirus (HPV) E6/E7 mRNA in clinical specimens. The automated platform performs chip-based sample preconcentration, nucleic acid extraction, amplification, and real-time fluorescent detection with minimal user interfacing. It consists of two modular prototypes, one for sample preparation and one for amplification and detection; however, a common interface is available to facilitate later integration into one single module. Nucleic acid extracts (n = 28) from cervical cytology specimens extracted on the sample preparation chip were tested using the PreTect HPV-Proofer and achieved an overall detection rate for HPV across all dilutions of 50%–85.7%. A subset of 6 clinical samples extracted on the sample preparation chip module was chosen for complete validation on the NASBA chip module. For 4 of the samples, a 100% amplification for HPV 16 or 33 was obtained at the 1 : 10 dilution for microfluidic channels that filled correctly. The modules of a “sample-in, answer-out” diagnostic platform have been demonstrated from clinical sample input through sample preparation, amplification and final detection.